Abaloparatide
Baseline BMD T-score can help determine first-line therapy for women with osteoporosis
Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a BMD T-score of at least –2.8 at the total hip or –3.1 at the lumbar spine at baseline, according to study findings.
Abaloparatide improves bone strength among women with osteoporosis
Women with osteoporosis receiving abaloparatide for 18 months followed by alendronate for 2 years had greater improvements in trabecular bone score than those receiving placebo, according to study findings.
FDA approves abaloparatide for men with osteoporosis at high risk for fracture
The FDA has approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture, according to an industry press release.
Despite effective new therapies, osteoporosis remains undiagnosed, untreated
During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back.
Abaloparatide increases BMD, improves bone turnover markers in men with osteoporosis
SAN DIEGO — Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone mineral density at the lumbar spine, total hip and femoral neck at 12 months compared with placebo, according to a speaker.